These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18566379)

  • 1. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.
    Gritzapis AD; Voutsas IF; Lekka E; Tsavaris N; Missitzis I; Sotiropoulou P; Perez S; Papamichail M; Baxevanis CN
    J Immunol; 2008 Jul; 181(1):146-54. PubMed ID: 18566379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.
    Lekka E; Gritzapis AD; Perez SA; Tsavaris N; Missitzis I; Mamalaki A; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2010 May; 59(5):715-27. PubMed ID: 19904532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties.
    Gritzapis AD; Fridman A; Perez SA; La Monica N; Papamichail M; Aurisicchio L; Baxevanis CN
    Vaccine; 2009 Dec; 28(1):162-70. PubMed ID: 19799847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
    Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
    Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
    Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.
    Lustgarten J; Theobald M; Labadie C; LaFace D; Peterson P; Disis ML; Cheever MA; Sherman LA
    Hum Immunol; 1997 Feb; 52(2):109-18. PubMed ID: 9077559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
    Gückel B; Stumm S; Rentzsch C; Marmé A; Mannhardt G; Wallwiener D
    Cancer Immunol Immunother; 2005 Feb; 54(2):129-40. PubMed ID: 15365776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain.
    Voutsas IF; Gritzapis AD; Mahaira LG; Salagianni M; Hofe EV; Kallinteris NL; Baxevanis CN
    Int J Cancer; 2007 Nov; 121(9):2031-2041. PubMed ID: 17634957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
    Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
    Cancer Immunol Immunother; 2009 May; 58(5):653-64. PubMed ID: 18820911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
    Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
    Zaks TZ; Rosenberg SA
    Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.
    Henle AM; Erskine CL; Benson LM; Clynes R; Knutson KL
    J Immunol; 2013 Jan; 190(1):479-88. PubMed ID: 23180824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T
    Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
    Fisk B; Blevins TL; Wharton JT; Ioannides CG
    J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.
    Kawashima I; Tsai V; Southwood S; Takesako K; Sette A; Celis E
    Cancer Res; 1999 Jan; 59(2):431-5. PubMed ID: 9927058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.